12/20
11:27 am
nvs
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
Neutral
Report
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick [Yahoo! Finance]
12/20
04:39 am
nvs
Sandoz Boss Warns There's a Climate Cost of Obesity Wonder Drugs [Yahoo! Finance]
Low
Report
Sandoz Boss Warns There's a Climate Cost of Obesity Wonder Drugs [Yahoo! Finance]
12/19
08:22 am
nvs
Borealis Biosciences Appoints Christian Hordo as CEO and Expands Series A Financing [Yahoo! Finance]
Low
Report
Borealis Biosciences Appoints Christian Hordo as CEO and Expands Series A Financing [Yahoo! Finance]
12/18
07:52 am
nvs
Novartis AG (NVS): Among the Oversold Global Stocks to Buy Right Now [Yahoo! Finance]
Low
Report
Novartis AG (NVS): Among the Oversold Global Stocks to Buy Right Now [Yahoo! Finance]
12/17
01:32 pm
nvs
NVS vs. LLY: Which Stock Should Value Investors Buy Now? [Yahoo! Finance]
Low
Report
NVS vs. LLY: Which Stock Should Value Investors Buy Now? [Yahoo! Finance]
12/13
02:42 pm
nvs
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO™ [Globe and Mail, The (Toronto, Canada)]
Low
Report
Novartis and the pan-Canadian Pharmaceutical Alliance achieve milestone agreement for PLUVICTO™ [Globe and Mail, The (Toronto, Canada)]
12/10
09:11 am
nvs
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
Low
Report
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer
12/10
09:07 am
nvs
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer [Yahoo! Finance]
Low
Report
Longer-term Novartis Kisqali® NATALEE data show durable reduction in distant recurrence in broad population of patients with early breast cancer [Yahoo! Finance]
12/9
09:28 pm
nvs
Health Canada approves Celltrion's Omlyclo™ (CT-P39), the first and only omalizumab biosimilar in Canada [Yahoo! Finance]
Low
Report
Health Canada approves Celltrion's Omlyclo™ (CT-P39), the first and only omalizumab biosimilar in Canada [Yahoo! Finance]
12/9
02:52 pm
nvs
Novartis Announces Positive Results From Late-Stage Study on Fabhalta [Yahoo! Finance]
Low
Report
Novartis Announces Positive Results From Late-Stage Study on Fabhalta [Yahoo! Finance]
12/8
03:30 pm
nvs
Tony Van Heugten, CTO of e-Vision Smart Optics, Inc., inducted in the 2024 Florida Inventors Hall of Fame
Low
Report
Tony Van Heugten, CTO of e-Vision Smart Optics, Inc., inducted in the 2024 Florida Inventors Hall of Fame
12/5
07:07 am
nvs
Meningitis Treatment Market to Reach US$ 234.8 Million by 2034 Amid Advancements in Diagnostics and Vaccination Programs [Yahoo! Finance]
Low
Report
Meningitis Treatment Market to Reach US$ 234.8 Million by 2034 Amid Advancements in Diagnostics and Vaccination Programs [Yahoo! Finance]
12/4
01:29 pm
nvs
European Stocks Gain, CAC Rises Ahead of No-Confidence Vote [Yahoo! Finance]
Low
Report
European Stocks Gain, CAC Rises Ahead of No-Confidence Vote [Yahoo! Finance]
12/4
11:28 am
nvs
Why Novartis (NVS) is a Top Growth Stock for the Long-Term [Yahoo! Finance]
Low
Report
Why Novartis (NVS) is a Top Growth Stock for the Long-Term [Yahoo! Finance]
12/4
08:11 am
nvs
Novartis AG (NYSE: NVS) was downgraded by analysts at HSBC Holdings plc from a "hold" rating to a "reduce" rating.
Low
Report
Novartis AG (NYSE: NVS) was downgraded by analysts at HSBC Holdings plc from a "hold" rating to a "reduce" rating.
12/2
11:40 am
nvs
Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14% [Yahoo! Finance]
Low
Report
Novartis' $2.9 Billion Huntington's Bet Sends PTC Stock Soaring Over 14% [Yahoo! Finance]
12/2
08:46 am
nvs
NovelMed Receives FDA IND Approval for NM8074 (Ruxoprubart), the First Anti-Bb Alternative Pathway Blocker for Treating Primary Immunoglobulin A Nephropathy (IgAN): A Renal Disorder [Yahoo! Finance]
Low
Report
NovelMed Receives FDA IND Approval for NM8074 (Ruxoprubart), the First Anti-Bb Alternative Pathway Blocker for Treating Primary Immunoglobulin A Nephropathy (IgAN): A Renal Disorder [Yahoo! Finance]
12/1
03:59 pm
nvs
2 Dividend Stocks to Buy and Hold Forever [Yahoo! Finance]
Low
Report
2 Dividend Stocks to Buy and Hold Forever [Yahoo! Finance]
11/30
02:29 am
nvs
Drugs Help Switzerland Withstand Pain From Swings in the Franc [Yahoo! Finance Canada]
Low
Report
Drugs Help Switzerland Withstand Pain From Swings in the Franc [Yahoo! Finance Canada]
11/30
02:25 am
nvs
Drugs Help Switzerland Withstand Pain From Swings in the Franc [Yahoo! Finance]
Low
Report
Drugs Help Switzerland Withstand Pain From Swings in the Franc [Yahoo! Finance]
11/29
06:40 am
nvs
Blood Culture Tests Market is Slated to Evolve at an Impressive 12.3% CAGR through 2031 | SkyQuest Technology [Yahoo! Finance]
Low
Report
Blood Culture Tests Market is Slated to Evolve at an Impressive 12.3% CAGR through 2031 | SkyQuest Technology [Yahoo! Finance]
11/28
01:42 pm
nvs
EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer [Yahoo! Finance]
Low
Report
EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer [Yahoo! Finance]
11/28
05:31 am
nvs
Formosa Pharmaceuticals and Medvisis Switzerland Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain [Yahoo! Finance]
Low
Report
Formosa Pharmaceuticals and Medvisis Switzerland Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain [Yahoo! Finance]
11/27
06:55 am
nvs
Treatment of Menopausal Hot Flashes: Global Industry Trends and Regional Market Opportunities 2025-2030 [Yahoo! Finance]
Low
Report
Treatment of Menopausal Hot Flashes: Global Industry Trends and Regional Market Opportunities 2025-2030 [Yahoo! Finance]
11/27
01:19 am
nvs
Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence [Yahoo! Finance]
Low
Report
Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence [Yahoo! Finance]